Goldman Sachs Rates Elanco Animal Health (ELAN) Buy

Goldman Sachs has reiterated its Buy rating on Elanco Animal Health Incorporated (NYSE: ELAN) and set a price target of $32. This update came on October 16, 2026, after the stock closed at $23.55. The new target suggests significant upside potential from its recent trading levels.

Goldman Sachs's Call on Elanco

Goldman Sachs's latest assessment reaffirms a positive outlook for Elanco, as the stock is currently trading at a price that is about 36% lower than the new target. The firm had previously not updated its target for Elanco, making this reiteration a notable moment for investors.

Other Institutional Activity in Elanco

In the latest reporting period, various institutional investors have also adjusted their stakes in Elanco. Dodge & Cox Inc. trimmed its holdings by 1,544,285 shares, leaving it with 67,397,025 shares valued at about $1.59 billion. FMR, LLC increased its stake by 6,024,363 shares, now holding 56,948,819 shares worth around $1.34 billion. Blackrock Inc. added 1,228,631 shares, bringing its total to 48,849,973 shares valued at approximately $1.15 billion. Primecap Management Company decreased its holdings by 394,217 shares to 45,445,012 shares, worth about $1.07 billion, while T. Rowe Price Investment Management, Inc. reduced its stake by 5,884,529 shares, leaving it with 28,750,719 shares valued at around $677 million.

Elanco Animal Health Incorporated Stock Up 4.4%

As of Friday, October 16, 2026, Elanco's shares traded at $23.55. This price is close to the 50-day moving average of $23.24 but below its 52-week high of $27.98. The stock is still slightly above its 52-week low of $19.40, indicating potential volatility in the near term.

Recent Earnings

In its most recent earnings report for the quarter ended December 31, 2025, Elanco reported revenue of approximately $5.02 billion, reflecting a growth of 10.2% year over year. The company had a negative earnings per share (EPS) of -$0.41, with a net margin of -3.96%. The next earnings report is scheduled for November 6, 2026.

Insider Buying and Selling at Elanco Animal Health Incorporated

Several insiders have recently purchased shares in Elanco. CEO Jeffrey Simmons bought 115 shares at an average price of $24.57 on June 26, 2026, totaling about $2,825.55. Director Kurzius Lawrence Erik acquired 40,000 shares on August 20, 2026, at $23.40, amounting to approximately $935,920. Officer O'Neill Shiv purchased 3,998 shares on August 18, 2026, at an average price of $23.58 for a total value of $94,273. Additionally, Director Harrington Michael J bought 5,000 shares on August 12, 2026, at $21.82, totaling around $109,100.

Analysts Set New Price Targets

Besides Goldman Sachs's recent update, UBS maintained a Buy rating on Elanco with a price target of $33 on August 6, 2026, up from a prior target of $31. Keybanc also kept its Overweight rating with a new target of $30, increasing from $29. Morgan Stanley maintained an Equal-Weight rating with a target increase to $26 from $23 on July 22, 2026. The consensus among analysts is a strong buy with a mean price target of about $31.07, based on 14 analyst opinions.

About Elanco Animal Health

Elanco Animal Health Incorporated is an animal health company that focuses on creating and marketing products for pets and farm animals worldwide. This focus on health products positions Elanco uniquely within the healthcare sector, allowing it to tap into a growing demand for animal care solutions.

Bottom Line

Elanco's shares are currently trading below Goldman Sachs's updated target price, which could signal growth potential ahead. With the next earnings report scheduled for November 6, investors will be watching closely for how the company performs. Remember, Goldman Sachs's rating reflects the position as of the recent update and might not represent ongoing investor actions.